ENDORESIST

  • Novel drug targeting antiestrogen therapy resistance: a paradigm shift in breast cancer treatment
  • ENDORESIST is a translational cancer research project which aims at seizing a major market opportunity by developing SCO-101, a new drug that targets anti-estrogen resistance in breast cancer. We will deliver a clinically validated and safe drug, and a companion diagnostic tool, opening the possibility to find a big pharma buyer/partner to capitalize on the SCO-101 opportunity. ENDORESIST builds around a patient-centric approach, based on biomarker discovery and insights on mechanisms of action.
  • ENDORESIST not yet started and will run for 30 month.
  • Partner to the ENDORESIST project are Scandion Oncology A/S and the Department of Medical Oncology of Erasmus MC, the University Medical Center Rotterdam. 2cureX sees an active exchange between hospital professionals and patients as key in future treatment of cancer patients.

Project Details

Acronym:
ENDORESIST

Duration:
36 months

Start date:
Not started

Topic:
New Treatments for Anti-estrogen Resistance

Funding:
2.2 Mio EUR

Upcoming events

January 21, 2021

Fight Cancer 2021, Redeye Event, Stockholm

Click here for more information

February 10, 2021

VATOR SWISS NORDIC BIO 2021 – The Annual Nordic Healthcare Investor Summit in Zürich

Read more

February 25, 2021

2cureX Year-End Report 2020

View previous reports

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.